FDA Approves Collagenase Santyl Ointment Manufacturing Facility

BioSpecifics Technologies Corp. (Lynbrook, NY) received FDA approval for a new manufacturing facility for Collagenase Santyl Ointment. The facility, located at its licensed distributor, consists of compounding, filling, precision packaging, and cartoning equipment.

Collagenase Santyl is FDA approved for second and third degree burns, and for the non-surgical treatment of chronic dermal ulcers and burn wounds. Collagenase acts by supplementing the natural process for removal of non-viable tissue at the wound site by catalyzing the breakdown of collagen. Non-viable wound tissue has the same 75% proportion of collagen as the rest of skin.

BioSpecifics Technologies Corp. is a biopharmaceutical company focused on wound healing and tissue remodeling. The company produces Collagenase ABC, the essential ingredient in Collagenase Santyl.

For more information: Thomas L. Wegman, Executive VP, BioSpecifics Technologies Corp., 35 Wilbur St., Lynbrook, NY 11563. Tel: 516-593-7000. Fax: 516-593-7039.

Edited by Jim Pomager